Moderna, Inc.: all 117 studies

Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• A Study of Updated mRNA Seasonal Influenza VaccinesNot yet recruitingNCT07884175Phase 4
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenNot yet recruitingNCT07870330Phase 1
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingNCT07863635Phase 4
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingNCT07808697Phase 2
• A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsRecruitingNCT07764237Phase 1
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeRecruitingNCT07478952Phase 1
• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07116616Phase 1/2
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsRecruitingNCT06880549Phase 1
• A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsRecruitingNCT06735248Phase 2
• A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsRecruitingNCT06655870Phase 1
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingNCT06585241Phase 4
• A Retrospective Study to Characterize Participants With Propionic AcidemiaRecruitingNCT05769621
• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsRecruitingNCT05533697Phase 1/2
• An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705RecruitingNCT05295433Phase 1/2
• A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyRecruitingNCT05130437Phase 1/2
• Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaRecruitingNCT04159103Phase 1/2
• A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of AgeCompletedNCT06634797Phase 4Results posted
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeCompletedNCT06602024Phase 3Results posted
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)CompletedNCT06508320Phase 2Results posted
• A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated AdultsCompletedNCT06354998Phase 3Results posted
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusCompletedNCT06097299Phase 2Results posted
• A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeCompletedNCT06097273Phase 3Results posted
• A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeCompletedNCT06060457Phase 3Results posted
• A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesCompletedNCT06033261Phase 1/2Results posted
• A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgeCompletedNCT05975099Phase 1/2Results posted
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy AdultsCompletedNCT05868382Phase 2Results posted
• Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedNCT05827978Phase 3Results posted
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsCompletedNCT05827926Phase 1/2Results posted
• A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy AdultsCompletedNCT05827068Phase 1/2Results posted
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19CompletedNCT05815498Phase 3Results posted
• Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsTerminatedNCT05584202Phase 2Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderCompletedNCT05566639Phase 3Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedNCT05415462Phase 3Results posted
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldCompletedNCT05375838Phase 1/2Results posted
• A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy AdultsCompletedNCT05333289Phase 1/2Results posted
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedNCT05330975Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19CompletedNCT05249829Phase 2/3Results posted
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedNCT05137236Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeCompletedNCT05127434Phase 2/3Results posted
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy AdultsCompletedNCT04956575Phase 1/2Results posted
• A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedNCT04927065Phase 2/3Results posted
• A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus AreasCompletedNCT04917861Phase 2Results posted
• A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult ParticipantsCompletedNCT04860297Phase 3Results posted
• A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCompletedNCT04796896Phase 2/3Results posted
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedNCT04649151Phase 2/3Results posted
• A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19CompletedNCT04470427Phase 3Results posted
• Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and OlderCompletedNCT04405076Phase 2Results posted
• Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsCompletedNCT04232280Phase 2Results posted
• Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative AdultsCompletedNCT04064905Phase 1Results posted
• Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy ParticipantsCompletedNCT03325075Phase 1Results posted
• Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced MalignanciesTerminatedNCT03323398Phase 1/2Results posted
• Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult SubjectsCompletedNCT03014089Phase 1Results posted
• A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsActive, not recruitingNCT07737717Phase 1
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)Active, not recruitingNCT07561294Phase 2
• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingNCT07266558Phase 4
• A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeCompletedNCT07117487Phase 3
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsCompletedNCT07089706Phase 4
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeCompletedNCT06864143Phase 2
• Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeCompletedNCT06694389Phase 3
• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisActive, not recruitingNCT06592794Phase 3
• Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During PregnancyCompletedNCT06369272
• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGEActive, not recruitingNCT06333704
• Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy ParticipantsCompletedNCT06243770Phase 1
• A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)Active, not recruitingNCT06189053
• A Dose-finding Study to Evaluate mRNA-3210 in Participants With PhenylketonuriaWithdrawnNCT06147856Phase 1/2
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersCompletedNCT06143046Phase 2
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsWithdrawnNCT06133010Phase 2
• Post-marketing Safety of Elasomeran/Davesomeran and AndusomeranCompletedNCT06130345
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 VaccineCompletedNCT06113692
• A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsCompletedNCT06067230Phase 3
• A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeCompletedNCT05995275Phase 1/2
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeCompletedNCT05992935Phase 1/2
• A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsCompletedNCT05972174Phase 1/2
• A Study of the Effectiveness of Moderna COVID-19 VaccineCompletedNCT05933304
• mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT05918250Phase 1
• Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19CompletedNCT05894590
• Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 VaccineCompletedNCT05894525
• Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19CompletedNCT05894499
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsActive, not recruitingNCT05831111Phase 1
• An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)CompletedNCT05765578
• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsActive, not recruitingNCT05743881Phase 1
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeTerminatedNCT05701800Phase 1
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingNCT05683457Phase 2
• A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart FailureCompletedNCT05659264Phase 1
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsCompletedNCT05606965Phase 2
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedNCT05585632Phase 1
• A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeCompletedNCT05575492Phase 1/2
• Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) StudyCompletedNCT05572658
• Use of Wearable Digital Sensors After mRNA Vaccination in AdultsCompletedNCT05440318
• A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeCompletedNCT05436834Phase 3
• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
• A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any KindCompletedNCT05367908
• A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised AdultsCompletedNCT05366322
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsActive, not recruitingNCT05164094Phase 1/2
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647CompletedNCT05105048Phase 1
• A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)Active, not recruitingNCT05095727Phase 1/2
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedNCT05085366Phase 3
• A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedNCT04975893Phase 2
• Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United StatesCompletedNCT04958954

← Moderna, Inc. overview and focus areas